Detail

Pamidronate

Description

Name: Pamidronate
Type: small molecule
Groups: approved
Indication: For the treatment of moderate or severe hypercalcemia associated with malignancy
Accession Number: DB00282 ( APRD01161)
Description: Pamidronic acid (INN) or pamidronate disodium (USAN), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. [Wikipedia]
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Arediapowder for solution60 mgintravenous31-12-199430-07-2001Canada
Aredia 30mgpowder for solution30 mgintravenous31-12-1994Canada
Aredia 90mgpowder for solution90 mgintravenous31-12-1994Canada
Aredia Liq Inj 3mg/mlliquid3 mgintravenous31-12-199209-09-1996Canada
Pamidronate Disodium for Injectionsolution3 mgintravenous31-08-2001Canada
Pamidronate Disodium for Injectionsolution6 mgintravenous31-08-2001Canada
Pamidronate Disodium for Injectionsolution9 mgintravenous31-08-2001Canada
Pamidronate Disodium for Injectionsolution3 mgintravenous01-03-2004Canada
Pamidronate Disodium for Injectionsolution6 mgintravenous02-03-2004Canada
Pamidronate Disodium for Injectionsolution9 mgintravenous01-03-2004Canada
Pamidronate Disodium for Injectionpowder for solution30 mgintravenous01-01-1970Canada
Pamidronate Disodium for Injectionpowder for solution90 mgintravenous01-01-1970Canada
Pamidronate Disodium for Injectionsolution3 mgintravenous12-07-2006Canada
Pamidronate Disodium for Injectionsolution6 mgintravenous12-07-2006Canada
Pamidronate Disodium for Injectionsolution9 mgintravenous12-07-2006Canada
Pamidronate Disodium Omega 3 mg/mlsolution3.0 mgintravenous18-04-2007Canada
Pamidronate Disodium Omega 6 mg/mlsolution6.0 mgintravenous24-05-2006Canada
Pamidronate Disodium Omega 9 mg/mlsolution9.0 mgintravenous27-07-2005Canada
PMS-pamidronatepowder for solution30 mgintravenous23-04-2003Canada
PMS-pamidronatepowder for solution90 mgintravenous23-04-2003Canada
PMS-pamidronatepowder for solution60 mgintravenous01-01-1970Canada
PMS-pamidronatepowder for solution15 mgintravenous01-01-1970Canada
Val-pamidronate Disodiumsolution9 mgintravenous01-11-201217-07-2015Canada

Generic Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Pamidronate Disodiuminjection, solution3 mg/mLintravenous19-05-2002US
Pamidronate Disodiuminjection, solution9 mg/mLintravenous19-05-2002US
Pamidronate Disodiuminjection, solution3 mg/mLintravenous01-04-2002US
Pamidronate Disodiuminjection, solution9 mg/mLintravenous01-04-2002US
Pamidronate Disodiuminjection3 mg/mLintravenous01-11-2008US
Pamidronate Disodiuminjection9 mg/mLintravenous01-11-2008US
Pamidronate Disodiuminjection3 mg/mLintravenous01-11-2008US
Pamidronate Disodiuminjection, solution3 mg/mLintravenous16-07-2010US
Pamidronate Disodiuminjection, solution9 mg/mLintravenous09-08-2010US
Pamidronate Disodiuminjection, solution3 mg/mLintravenous10-05-2011US
Pamidronate Disodiuminjection, solution9 mg/mLintravenous10-05-2011US
Pamidronate Disodiuminjection9 mg/mLintravenous01-11-2008US
Pamidronate Disodiuminjection, solution3 mg/mLintravenous10-05-2011US
Pamidronate Disodiuminjection, powder, lyophilized, for solution3 mg/mLintravenous06-08-2013US
Pamidronate Disodiuminjection, powder, lyophilized, for solution6 mg/mLintravenous06-08-2013US
Pamidronate Disodiuminjection, powder, lyophilized, for solution9 mg/mLintravenous06-08-2013US
Pamidronate Disodiuminjection3 mg/mLintravenous15-01-2010US
Pamidronate Disodiuminjection9 mg/mLintravenous15-01-2010US
Pamidronate Disodiuminjection, solution3 mg/mLintravenous27-06-2002US
Pamidronate Disodiuminjection, solution6 mg/mLintravenous27-06-2002US
Pamidronate Disodiuminjection, solution9 mg/mLintravenous27-06-2002US

Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Pamidronate DisodiumPamidronate
Aredia 90mgPamidronate
Aredia 30mgPamidronate
Pamidronate Disodium for InjectionPamidronate
Pamidronate Disodium for InjectionPamidronate
Pamidronate Disodium for InjectionPamidronate
PMS-pamidronatePamidronate
PMS-pamidronatePamidronate
Pamidronate Disodium for InjectionPamidronate
Pamidronate Disodium for InjectionPamidronate
Pamidronate Disodium for InjectionPamidronate
Pamidronate Disodium Omega 3 mg/mlPamidronate
Pamidronate Disodium Omega 6 mg/mlPamidronate
Pamidronate Disodium Omega 9 mg/mlPamidronate
Pamidronate Disodium for InjectionPamidronate
Pamidronate Disodium for InjectionPamidronate
Pamidronate Disodium for InjectionPamidronate
Aredia Liq Inj 3mg/mlPamidronate
ArediaPamidronate
Val-pamidronate DisodiumPamidronate
PMS-pamidronatePamidronate
PMS-pamidronatePamidronate
Pamidronate Disodium for InjectionPamidronate
Pamidronate Disodium for InjectionPamidronate

Categories
  • Bone Density Conservation Agents
  • Bisphosphonates

Pharmacology

Indication: For the treatment of moderate or severe hypercalcemia associated with malignancy
Pharmacodynamics: Not Available
Mechanism of action: The mechanism of action of pamidronate is inhibition of bone resorption. Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Pamidronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Absorption: Plasma concentration rises rapidly upon IV administration.
Volume of distribution: Not Available
Protein binding: Approximately 54% to human serum proteins.
Metabolism: Not Available
Route of elimination: Pamidronate is not metabolized and is exclusively eliminated by renal excretion.
Half life: The mean ± SD elimination half-life is 28 ± 7 hours
Clearance: Not Available
Toxicity: Side effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Novartis pharmaceuticals corp
  • Aesgen inc
  • Akorn strides llc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Cipla ltd
  • Generamedix inc
  • Hospira inc
  • Mn pharmaceuticals
  • Pharmaforce inc
  • Pliva lachema as
  • Sun pharma global inc
  • Teva parenteral medicines inc

Packagers:
Dosage forms
FormRouteStrength
Powder for solutionintravenous60 mg
Powder for solutionintravenous30 mg
Powder for solutionintravenous90 mg
Liquidintravenous3 mg
Injectionintravenous3 mg/mL
Injectionintravenous9 mg/mL
Injection, powder, lyophilized, for solutionintravenous3 mg/mL
Injection, powder, lyophilized, for solutionintravenous6 mg/mL
Injection, powder, lyophilized, for solutionintravenous9 mg/mL
Injection, solutionintravenous3 mg/mL
Injection, solutionintravenous6 mg/mL
Injection, solutionintravenous9 mg/mL
Solutionintravenous3 mg
Solutionintravenous6 mg
Solutionintravenous9 mg
Solutionintravenous3.0 mg
Solutionintravenous6.0 mg
Solutionintravenous9.0 mg
Powder for solutionintravenous15 mg

Prices
Unit descriptionCostUnit
Pamidronate Disodium 30 mg/vial$86.09vial
Pamidronate Disodium Omega 30 mg/vial$86.09vial
Pamidronate disod 30 mg vial$111.94each
Pamidronate Disodium 60 mg/vial$129.14vial
Aredia 30 mg/vial$182.69vial
Pamidronate Disodium 90 mg/vial$258.28vial
Pamidronate Disodium Omega 90 mg/vial$258.28vial
Pms-Pamidronate 90 mg/vial$258.28vial
Aredia 30 mg vial$279.86each
Aredia 90 mg/vial$548.05vial
Pamidronate disod 90 mg vial$755.64each
Aredia 90 mg vial$839.59each

Patents
CountryPatent NumberApprovedExpires (estimated)

Interactions

Drug Interactions
DrugInteraction
AmikacinAmikacin may increase the activities of Pamidronate.
ArbekacinArbekacin may increase the activities of Pamidronate.
AxitinibThe risk or severity of adverse effects can be increased when Axitinib is combined with Pamidronate.
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Pamidronate.
CabozantinibThe risk or severity of adverse effects can be increased when Cabozantinib is combined with Pamidronate.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pamidronate.
DeferasiroxThe risk or severity of adverse effects can be increased when Pamidronate is combined with Deferasirox.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pamidronate.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pamidronate.
EsomeprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Esomeprazole.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Pamidronate.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pamidronate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pamidronate.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pamidronate.
FramycetinFramycetin may increase the activities of Pamidronate.
GentamicinGentamicin may increase the activities of Pamidronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pamidronate.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pamidronate.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Pamidronate.
KanamycinKanamycin may increase the activities of Pamidronate.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pamidronate.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pamidronate.
LansoprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Lansoprazole.
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Pamidronate.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pamidronate.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pamidronate.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pamidronate.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pamidronate.
NeomycinNeomycin may increase the activities of Pamidronate.
NetilmicinNetilmicin may increase the activities of Pamidronate.
OmeprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Omeprazole.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pamidronate.
PantoprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Pantoprazole.
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Pamidronate.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pamidronate.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Pamidronate.
RabeprazoleThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Rabeprazole.
RamucirumabThe risk or severity of adverse effects can be increased when Ramucirumab is combined with Pamidronate.
RegorafenibThe risk or severity of adverse effects can be increased when Regorafenib is combined with Pamidronate.
RibostamycinRibostamycin may increase the activities of Pamidronate.
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Pamidronate.
SpectinomycinSpectinomycin may increase the activities of Pamidronate.
StreptomycinStreptomycin may increase the activities of Pamidronate.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pamidronate.
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Pamidronate.
ThalidomideThalidomide may increase the nephrotoxic activities of Pamidronate.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pamidronate.
TobramycinTobramycin may increase the activities of Pamidronate.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pamidronate.
VandetanibThe risk or severity of adverse effects can be increased when Vandetanib is combined with Pamidronate.

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • 1,3-aminoalcohols
  • Hydrocarbon derivatives
  • Monoalkylamines
  • Organic phosphonic acids
  • Organooxygen compounds

substituent:
  • 1,3-aminoalcohol
  • Aliphatic acyclic compound
  • Amine
  • Bisphosphonate
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organooxygen compound
  • Organophosphonic acid
  • Primary aliphatic amine
  • Primary amine

References

Synthesis Reference: Edward C. Shinal, "Method for preparation of disodium pamidronate." U.S. Patent US6268524, issued February, 1988.
General Reference: # Zarychanski R, Elphee E, Walton P, Johnston J: Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006 Jan;81(1):73-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16369966
External Links:
ResourceLink
RxListhttp://www.rxlist.com/cgi/generic/aredia.htm
Drugs.comhttp://www.drugs.com/cdi/pamidronate.html

ATC Codes:
  • Array

AHFS Codes:
  • 92:00.00

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?